Insider Trading Alert - Opko Health And 3 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 11, 2013, 51 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $33.26 to $7,200,000.00.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 8,500 shares at $9.93 on Oct. 11, 2013. Following this transaction, the CEO & Chairman owned 136.8 million shares meaning that the stake was reduced by 0.01% with the 8,500 share transaction.

The shares most recently traded at $9.95, up $0.02, or 0.19% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 24-Week # shares bought: 4,300

The average volume for Opko Health has been 2.7 million shares per day over the past 30 days. Opko Health has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are up 81.5% year to date as of the close of trading on Friday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Usana Health (USNA) - FREE Research Report

Gull Holdings Ltd who is 10% Owner at Usana Health sold 7,000 shares at $80.08 on Oct. 11, 2013. Following this transaction, the 10% Owner owned 6.6 million shares meaning that the stake was reduced by 0.11% with the 7,000 share transaction.

Wentz Myron W who is Director at Usana Health sold 7,000 shares at $80.08 on Oct. 11, 2013. Following this transaction, the Director owned 6.6 million shares meaning that the stake was reduced by 0.11% with the 7,000 share transaction.

The shares most recently traded at $83.44, up $3.36, or 4.03% since the insider transaction. Historical insider transactions for Usana Health go as follows:

  • 4-Week # shares sold: 7,000
  • 12-Week # shares sold: 14,000
  • 24-Week # shares sold: 35,000

The average volume for Usana Health has been 137,500 shares per day over the past 30 days. Usana Health has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 156.88% year to date as of the close of trading on Friday.

USANA Health Sciences, Inc. develops, manufactures, distributes, and sells nutritional and personal care products worldwide. The company has a P/E ratio of 15.6. Currently there are no analysts that rate Usana Health a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on USNA - FREE

TheStreet Quant Ratings rates Usana Health as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Usana Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Health Care REIT (HCN) - FREE Research Report

Herman Charles J Jr who is EVP & Chief Investment Officer at Health Care REIT sold 833 shares at $62.47 on Oct. 11, 2013. Following this transaction, the EVP & Chief Investment Officer owned 42,239 shares meaning that the stake was reduced by 1.93% with the 833 share transaction.

The shares most recently traded at $62.04, down $0.43, or 0.7% since the insider transaction. Historical insider transactions for Health Care REIT go as follows:

  • 12-Week # shares sold: 250
  • 24-Week # shares sold: 12,351

The average volume for Health Care REIT has been 1.8 million shares per day over the past 30 days. Health Care REIT has a market cap of $18.1 billion and is part of the financial sector and real estate industry. Shares are up 2.9% year to date as of the close of trading on Friday.

Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The stock currently has a dividend yield of 4.85%. The company has a P/E ratio of 81.9. Currently there are 6 analysts that rate Health Care REIT a buy, 2 analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCN - FREE

TheStreet Quant Ratings rates Health Care REIT as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and poor profit margins. Get the full Health Care REIT Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

RF Micro Devices (RFMD) - FREE Research Report

Bruggeworth Robert A who is President and CEO at RF Micro Devices sold 50,000 shares at $6.00 on Oct. 11, 2013. Following this transaction, the President and CEO owned 1.4 million shares meaning that the stake was reduced by 3.47% with the 50,000 share transaction.

Priddy William A who is VP Administration and CFO at RF Micro Devices sold 21,367 shares at $6.00 on Oct. 11, 2013. Following this transaction, the VP Administration and CFO owned 779,597 shares meaning that the stake was reduced by 2.67% with the 21,367 share transaction.

The shares most recently traded at $5.88, down $0.12, or 2.04% since the insider transaction. Historical insider transactions for RF Micro Devices go as follows:

  • 4-Week # shares sold: 88,485
  • 12-Week # shares sold: 415,212
  • 24-Week # shares sold: 802,488

The average volume for RF Micro Devices has been 4.4 million shares per day over the past 30 days. RF Micro Devices has a market cap of $1.6 billion and is part of the technology sector and electronics industry. Shares are up 28.79% year to date as of the close of trading on Friday.

RF Micro Devices, Inc. engages in the design, development, manufacture, and marketing of radio frequency (RF) solutions for original equipment manufacturers and original design manufacturers in wireless and wired communications applications in the United States and internationally. Currently there are 12 analysts that rate RF Micro Devices a buy, 2 analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RFMD - FREE

TheStreet Quant Ratings rates RF Micro Devices as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full RF Micro Devices Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices